Aminotransferases serve as indispensable biochemical bridges between nitrogen metabolism and cellular energy production, operating at the fundamental crossroads of amino acid catabolism and carbohydrate synthesis. By orchestrating the reversible transfer of amino groups, these ubiquitous enzymes facilitate metabolic homeostasis across every major organ system while offering clinicians one of medicine’s most enduring diagnostic windows into tissue integrity and organ pathology.
Aminotransferase
1. Concise Definition
An aminotransferase (commonly referred to as a transaminase) is an enzyme belonging to the transferase family (Enzyme Commission class EC 2.6.1) that catalyzes the reversible transfer of an amino group (−NH2) from an amino acid to an α-keto acid. This enzymatic transformation yields a new amino acid and a corresponding α-keto acid without releasing free ammonia into the cellular milieu. In human physiology, these enzymes rely on the essential cofactor pyridoxal phosphate (PLP), the active derivative of vitamin B6, to execute nitrogen shuttling.
Beyond basic substrate interconversion, aminotransferases fulfill a central role in maintaining systemic metabolic equilibrium. They funnel nitrogenous waste toward the urea cycle, provide carbon skeletons for the tricarboxylic acid (TCA) cycle and gluconeogenesis, and synthesize non-essential amino acids on metabolic demand. Clinically, specific aminotransferases—most notably alanine aminotransferase (ALT) and aspartate aminotransferase (AST)—serve as ubiquitous serum biomarkers whose elevation indicates hepatocyte injury, skeletal muscle damage, or cardiac necrosis.
2. Etymology & Linguistic Origin
The term aminotransferase is derived from a composite of classical linguistic roots and biochemical nomenclature conventions. The prefix amino- originates from the chemical radical containing nitrogen, rooted in ammonia, which historically derives from the Greek Amm&omacron;niakón (Αμμωνιακóν), referencing the salts gathered near the Temple of Ammon in ancient Libya. The stem transfer originates from the Latin verb transferre, meaning “to bear across” or “to carry over” (from trans-, “across,” and ferre, “to bear”). The terminal suffix -ase is the universally recognized biological designation denoting an enzyme, adapted from the French diastase in the mid-nineteenth century.
Historically, these biological catalysts were termed transaminases, a term introduced in the late 1930s following the seminal biochemical identification of transamination reactions. While contemporary International Union of Biochemistry and Molecular Biology (IUBMB) guidelines officially favor aminotransferase to emphasize the exact chemical group being relocated, both designations persist synonymously throughout professional medical literature and laboratory medicine.
3. Pronunciation & Grammatical Form
Pronunciation: /əˌmiːnoʊˈtrænsfəˌreɪs/ or /əˌmaɪnoʊˈtrænzfəˌreɪz/.
Part of Speech: Noun (countable).
Plural Form: Aminotransferases.
Grammatical Variants and Derivatives:
- Transaminase (noun; clinical synonym).
- Transamination (noun; the physiological or biochemical chemical process catalyzed by the enzyme).
- Transaminate (verb; the act of transferring an amino functional moiety).
- Aminotransferasic (adjective; rare, describing phenomena related to aminotransferase kinetics).
4. Detailed Conceptual Explanation
The fundamental biological role of aminotransferases resides in their capacity to redistribute nitrogen without liberating toxic free ammonium ions within the intracellular environment. The general reaction can be summarized by the stoichiometry: Amino Acid 1 + α-Keto Acid 2 ⇔ α-Keto Acid 1 + Amino Acid 2. In the vast majority of physiological pathways, glutamate and α-ketoglutarate act as one of the obligate substrate pairs. Because the net standard Gibbs free energy change (ΔG°’) of transamination reactions hovers near zero, these pathways are freely reversible, with the prevailing intracellular substrate-to-product concentration ratios determining the net direction of catalytic flow.
The enzymatic mechanism operates via a double-displacement or classical “ping-pong bi-bi” catalytic model. Central to this process is the non-covalent or Schiff-base-linked binding of transamination intermediates to the prosthetic group, pyridoxal 5′-phosphate (PLP), which is covalently tethered to a specific active-site lysine residue through an internal aldimine bond. When an amino acid substrate enters the catalytic cleft, its amino group displaces the lysine residue to form an external aldimine with PLP. Subsequent base-catalyzed proton abstraction, electron delocalization across the conjugated pyridine ring (acting as an “electron sink”), and hydrolysis liberate the first product—an α-keto acid—while converting the enzyme-bound cofactor into pyridoxamine 5′-phosphate (PMP).
In the second half-reaction of the catalytic cycle, a distinct α-keto acid substrate enters the active site and condenses with PMP, forming a ketimine intermediate. Through an exact reversal of the preceding electronic rearrangements, the enzyme reconstructs the internal aldimine with its lysine residue, regenerating PLP and releasing the newly generated amino acid. This sequential Ping-Pong pathway enables efficient nitrogen swapping between diverse carbon backbones without requiring adenosine triphosphate (ATP) hydrolysis.
Beyond this universal catalytic cycle, aminotransferases exhibit distinct compartmentalization across subcellular architectures. For example, while alanine aminotransferase operates predominantly within the cytoplasm of hepatocytes, aspartate aminotransferase exists as two genetically and structurally distinct isoenzymes: cytosolic AST (cAST) and mitochondrial AST (mAST). This differential spatial localization dictates metabolic compartmentalization, linking cytosolic glycolysis with the mitochondrial electron transport chain through pathways such as the malate-aspartate shuttle.
5. Historical Development
The discovery of biological transamination represents a landmark chapter in twentieth-century intermediary metabolism. In 1937, Soviet biochemists Alexander E. Braunstein and Maria G. Kritzmann discovered that pigeon breast muscle homogenates possessed the enzymatic capacity to transfer the amino group from glutamic acid to pyruvic acid without producing detectable inorganic ammonia. This revelation challenged the longstanding dogma that amino acid catabolism occurred exclusively via spontaneous or oxidative deamination, fundamentally reshaping scientific models of cellular nitrogen balance.
During the 1940s and 1950s, international teams deciphered the cofactor requirements and structural architecture of the reaction. Esmond E. Snell demonstrated that vitamin B6 derivatives—specifically pyridoxal and pyridoxamine—acted as essential biological cofactors in model non-enzymatic transamination systems, clarifying the functional mechanism of PLP-dependent enzymes. Concurrently, Arthur Kornberg and colleagues characterized the enzymology of purified transaminases, validating the ping-pong bi-bi model and confirming the ubiquitous nature of transamination throughout bacterial, plant, and mammalian tissues.
The paradigm shift from basic biochemistry to routine clinical diagnostics occurred in 1954–1955 through the pioneering research of Felix Wróblewski and John S. LaDue at the Memorial Center for Cancer and Allied Diseases in New York. Wróblewski and LaDue observed that serum glutamic-oxaloacetic transaminase (SGOT, now AST) and serum glutamic-pyruvic transaminase (SGPT, now ALT) demonstrated profound elevations following acute myocardial infarction and acute viral or toxic hepatitis. The subsequent development of standardized coupled-enzyme spectrophotometric assays in the 1970s by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) firmly established aminotransferase quantification as the clinical benchmark for hepatic and cellular injury assessment globally.
6. Theoretical Foundations
The structural and functional dynamics of aminotransferases are understood through three foundational scientific paradigms: structural enzymology, thermodynamic metabolic control, and cellular membrane permeability theory. From a structural standpoint, the vast majority of mammalian aminotransferases belong to the Fold Type I class of PLP-dependent enzymes. These proteins fold as homodimers, wherein each monomer contributes critical catalytic amino acid residues to construct the active sites at the subunit interface. Dimerization is functionally mandatory: disruption of the quaternary assembly completely abolishes catalytic capacity, as residues from both adjacent polypeptide chains coordinate the phosphate group and aromatic ring of PLP.
From the perspective of metabolic systems theory, aminotransferases function as the primary thermodynamic buffers of intermediary metabolism. Because they catalyze reactions with equilibrium constants (Keq) close to unity, they operate near thermodynamic equilibrium under basal in vivo conditions. Consequently, flux through an aminotransferase is controlled almost entirely by mass action: shifts in the intracellular availability of pyruvate, oxaloacetate, or α-ketoglutarate instantly shift nitrogen into or out of the amino acid pool. This allows instantaneous adaptation to nutritional transitions, such as shifts between the fed state (characterized by amino acid oxidation and protein synthesis) and the fasted state (characterized by gluconeogenesis and ureagenesis).
Finally, the clinical application of aminotransferases is grounded in the cell membrane disruption model of biomarker release. Aminotransferases are strictly intracellular enzymes with no known extracellular physiological function. The baseline activity measured in normal peripheral blood represents physiological turnover and senescence of hepatocytes and muscle cells. When cell membranes undergo ischemic injury, toxic peroxidation, mechanical shear, or immunologically mediated lysis, the loss of structural membrane integrity allows cytosolic contents to leak down steep concentration gradients into the interstitial space and systemic circulation. The magnitude and kinetics of serum transaminase elevation correlate directly with the severity, acute nature, and subcellular depth of tissue necrosis.
7. Key Components, Types & Dimensions
The human genome encodes multiple distinct aminotransferases, each specialized for specific substrate pairs, subcellular locations, and organ systems:
- Alanine Aminotransferase 1 and 2 (ALT1, ALT2 / EC 2.6.1.2): Catalyzes the reaction: L-alanine + α-ketoglutarate ⇔ pyruvate + L-glutamate. ALT1 is highly expressed in hepatocytes, making it the most specific serum biomarker for hepatocellular parenchymal injury. ALT2 is expressed in lower quantities in skeletal muscle, adipose tissue, and the brain.
- Aspartate Aminotransferase (AST / EC 2.6.1.1): Catalyzes the reaction: L-aspartate + α-ketoglutarate ⇔ oxaloacetate + L-glutamate. Exists as two distinct isoenzymes: cytosolic AST (cAST, encoded by GOT1) and mitochondrial AST (mAST, encoded by GOT2). Widely distributed across the liver, cardiac muscle, skeletal muscle, kidneys, brain, and red blood cells.
- Branched-Chain Amino Acid Aminotransferase (BCAT / EC 2.6.1.42): Directs the initial catabolism of leucine, isoleucine, and valine into their corresponding α-keto acids. Expressed predominantly in skeletal muscle and nervous tissue rather than the liver, protecting the hepatic parenchyma from excessive nitrogen flux from branched-chain substrates.
- Tyrosine Aminotransferase (TAT / EC 2.6.1.5): A liver-specific cytoplasmic enzyme that initiates the degradation of tyrosine. Mutations in human TAT cause type II tyrosinemia, an inborn error of metabolism leading to oculocutaneous lesions and intellectual disability.
- γ-Aminobutyric Acid Transaminase (GABA-T / EC 2.6.1.19): Localized within mitochondrial compartments of the central nervous system, this enzyme degrades the primary inhibitory neurotransmitter GABA into succinic semialdehyde. Pharmacological inhibition of GABA-T elevates central GABA concentrations, forming the therapeutic basis for certain anticonvulsant regimens.
- Kynurenine Aminotransferase (KAT / EC 2.6.1.7): Operates along the tryptophan degradation pathway to convert kynurenine into kynurenic acid, an endogenous neuroprotective antagonist of NMDA and α7-nicotinic receptors implicated in psychiatric pathology.
8. Examples & Illustrative Cases
The diagnostic utility of aminotransferases is best understood through real-world clinical patterns, where the magnitude of elevation and the ratio of specific enzymes provide differential diagnostic clarity:
Case 1: Acute Toxic Hepatocellular Necrosis. A 28-year-old individual presents to the emergency department twelve hours after an intentional overdose of acetaminophen (paracetamol). Initial laboratory testing demonstrates massive serum transaminase elevations: ALT is measured at 8,400 U/L (reference: 7–56 U/L) and AST at 11,200 U/L (reference: 10–40 U/L). This extreme magnitude (>1,000 U/L, frequently exceeding 5,000 U/L) reflects widespread centrilobular hepatocyte necrosis caused by toxic N-acetyl-p-benzoquinone imine (NAPQI) accumulation, distinguishing acute toxic or ischemic injury from insidious chronic liver conditions.
Case 2: Alcoholic Hepatitis and the De Ritis Ratio. A 49-year-old chronic alcohol-dependent patient presents with jaundice, right upper quadrant abdominal tenderness, and ascites. Serum biochemistry reveals an AST of 240 U/L and an ALT of 95 U/L. Here, the elevations are moderate (rarely exceeding 300–500 U/L in alcoholic liver injury), but the AST:ALT ratio (the classic De Ritis ratio) is approximately 2.5:1. This inversion occurs because alcohol impairs hepatic pyridoxal 5′-phosphate stores (which suppresses ALT synthesis more profoundly than AST) and causes direct mitochondrial injury, selectively liberating mitochondrial AST into the circulation.
Case 3: Non-Hepatic Isolated AST Elevation (Rhabdomyolysis). A 34-year-old marathon runner collapses at the finish line and is brought to an acute care facility. Laboratory evaluation indicates an AST of 480 U/L alongside a completely normal ALT of 22 U/L and normal total bilirubin. A concurrent total creatine kinase (CK) measurement is markedly elevated at 45,000 U/L. This clinical picture illustrates that isolated AST elevations, in the absence of ALT abnormalities or other markers of cholestasis, frequently originate from skeletal muscle breakdown rather than intrinsic liver injury.
9. Measurement & Assessment
Contemporary clinical laboratories assess aminotransferase activity through automated, continuous-monitoring spectrophotometric assays standardized according to IFCC reference procedures. These methodologies monitor the change in optical absorbance at 340 nanometers (nm) caused by the oxidation of reduced nicotinamide adenine dinucleotide (NADH) to NAD+ via coupled enzymatic indicator systems:
For ALT determination, the primary transamination of L-alanine and α-ketoglutarate produces pyruvate. The indicator enzyme lactate dehydrogenase (LDH) immediately reduces this pyruvate to L-lactate, stoichiometrically consuming one molecule of NADH for every molecule of pyruvate processed. The rate of absorbance decrease at 340 nm is directly proportional to the catalytic activity of ALT in the patient sample:
Alanine + α-Ketoglutarate —(ALT)→ Pyruvate + Glutamate
Pyruvate + NADH + H+ —(LDH)→ Lactate + NAD+
For AST determination, the transamination between L-aspartate and α-ketoglutarate yields oxaloacetate. The coupled indicator enzyme malate dehydrogenase (MDH) reduces this oxaloacetate to L-malate, likewise consuming NADH in an equimolar ratio:
Aspartate + α-Ketoglutarate —(AST)→ Oxaloacetate + Glutamate
Oxaloacetate + NADH + H+ —(MDH)→ Malate + NAD+
Pre-analytical variables critically influence the accuracy of these measurements. In vitro hemolysis severely invalidates AST quantification because human erythrocytes contain AST concentrations up to 40 times higher than baseline serum; red blood cell rupture falsely inflates AST results while exerting minimal effects on ALT. Strenuous eccentric exercise within 48 to 72 hours of venipuncture can elevate circulating AST and ALT levels from mechanical muscle fiber microtrauma. Furthermore, patients with severe end-stage renal disease or advanced malnutrition often have depleted circulating pyridoxal phosphate, which can cause falsely depressed baseline transaminase readings unless the assay reagent is explicitly supplemented with exogenous PLP.
10. Applications & Practical Significance
The practical applications of aminotransferase testing extend across clinical hepatology, cardiology, occupational medicine, and drug development:
Clinical Hepatology: Aminotransferases represent the core component of routine comprehensive metabolic panels (CMPs) and liver function tests (LFTs). They are used to screen for, diagnose, and monitor chronic viral hepatitis (HBV, HCV), autoimmune hepatitis, hereditary hemochromatosis, Wilson disease, and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). Transient or sustained elevations serve as triggers for subsequent diagnostic evaluations, including abdominal ultrasonography, viral serologies, and liver biopsy.
Pharmaceutical Safety and Toxicological Profiling: Because the liver is the primary site of xenobiotic metabolism, drug-induced liver injury (DILI) represents a leading cause of candidate attrition during clinical trials and post-marketing regulatory withdrawals. Regulatory bodies like the United States Food and Drug Administration (FDA) employ “Hy’s Law”—which evaluates concurrent aminotransferase elevations exceeding three times the upper limit of normal (>3× ULN) alongside elevated total bilirubin (>2× ULN) without alkaline phosphatase elevation—as a predictive indicator of life-threatening hepatotoxicity.
Cardiovascular and Critical Care Medicine: Although AST has been entirely superseded by cardiac troponins I and T for the primary diagnosis of acute coronary syndromes, tracking AST kinetics remains useful in critical care units. It helps assess systemic hypoperfusion, “shock liver” (ischemic hepatitis), right-sided congestive heart failure, and multi-organ dysfunction syndrome (MODS).
Neurobiology and Psychopharmacology: Beyond serum biomarkers, understanding aminotransferases within the central nervous system has driven significant therapeutic discoveries. Pharmacological inhibition of γ-aminobutyric acid transaminase by the suicide inhibitor vigabatrin remains a potent, targeted strategy for managing refractory focal epilepsy and infantile spasms by directly elevating inhibitory GABAergic tone in the cerebral cortex.
11. Research & Empirical Evidence
Extensive clinical and epidemiological research over the past several decades has refined our understanding of aminotransferases in population health and disease progression:
Large-scale population studies, including data from the United States National Health and Nutrition Examination Survey (NHANES) and European health cohorts, have demonstrated that traditional clinical reference ranges for ALT frequently underestimate the presence of occult liver disease. Researchers such as Prati et al. (2002) demonstrated that historically established upper limits of normal (ULN)—frequently set at 40 to 50 U/L—were derived from historical donor pools that inadvertently included individuals with subclinical non-alcoholic fatty liver disease, undetected hepatitis C, or elevated body mass indexes (BMI). Contemporary guidelines increasingly advocate for lower reference cutoffs (approximately 29–33 U/L for adult males and 19–25 U/L for adult females) to maximize clinical sensitivity for early steatohepatitis.
In addition, aminotransferases serve as critical continuous variables in validated, non-invasive risk stratification algorithms. The Fibrosis-4 (FIB-4) index (which incorporates age, AST, ALT, and platelet count) and the AST-to-Platelet Ratio Index (APRI) are widely endorsed by international guidelines to triage patients with chronic viral hepatitis or metabolic liver disease, predicting advanced hepatic fibrosis and cirrhosis without the immediate necessity of an invasive percutaneous needle biopsy.
Genome-wide association studies (GWAS) have identified specific genetic loci that modulate baseline aminotransferase concentrations independently of lifestyle factors. Variations in the patatin-like phospholipase domain-containing protein 3 (PNPLA3, specifically the I148M variant) and transmembrane 6 superfamily member 2 (TM6SF2) genes are robustly associated with elevated baseline ALT and AST levels, conferring increased susceptibility to hepatic steatosis, progressive fibrosis, and hepatocellular carcinoma.
12. Cultural & Cross-Cultural Considerations
Interpreting aminotransferase values requires careful contextualization across global demographics, healthcare delivery settings, and regional genetic backgrounds:
Reference ranges are not universally standardized across international health systems. Variations in diagnostic instrumentation, reagent composition (such as automated PLP pre-incubation), and demographic reference populations result in substantial discrepancies between clinical laboratories in North America, Western Europe, and East Asia. Clinical practice guidelines published by the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Asian Pacific Association for the Study of the Liver (APASL) reflect subtle regional differences in diagnostic thresholds, particularly regarding the initiation of antiviral therapy for chronic hepatitis B.
Furthermore, cultural practices and dietary traditions influence baseline transaminase variability. The widespread consumption of traditional herbal remedies, dietary supplements, and indigenous botanicals (such as preparations containing kava, comfrey, or certain high-dose green tea extracts) can trigger idiosyncratic drug-induced liver injury that may be misattributed to viral or metabolic disease. Similarly, global variations in alcohol consumption patterns, the regional prevalence of metabolic syndrome, and disparities in universal hepatitis B vaccination programs alter the pre-test probability of finding elevated serum aminotransferases across diverse populations.
13. Criticisms, Debates & Limitations
Despite their established role in modern medicine, reliance on serum aminotransferases presents several clinical and diagnostic challenges:
Lack of Organ Specificity: A primary limitation of AST is its presence across numerous non-hepatic tissues. Elevated AST levels are frequently misdiagnosed as liver disease in patients experiencing occult polymyositis, vigorous athletic conditioning, unnoticed macro-trauma, or hemolytic disorders. Even ALT, historically considered exclusively liver-specific, can demonstrate mild serum elevations in severe rhabdomyolysis.
The Fallacy of Normalcy in Cirrhosis: A common diagnostic trap is the assumption that normal serum aminotransferases guarantee a healthy liver. In end-stage liver cirrhosis, progressive parenchymal extinction can deplete the total mass of surviving hepatocytes to such an extent that serum ALT and AST concentrations normalize (“pseudonormalization”). Normal transaminase levels may therefore obscure advanced liver fibrosis or architectural collapse.
The Challenge of Macro-AST: A benign diagnostic anomaly is macro-aspartate aminotransferase (macro-AST), a phenomenon wherein AST forms high-molecular-weight complexes with circulating immunoglobulins (predominantly IgG). These macro-complexes evade normal renal and reticuloendothelial clearance, leading to chronic, isolated, and marked elevations of serum AST in completely healthy individuals. Failure to identify macro-AST can result in unnecessary, expensive, and invasive clinical evaluations, including sequential imaging and unnecessary liver biopsies.
14. Related Terms & Distinctions
Distinguishing aminotransferases from associated biochemical constructs is critical for accurate clinical and pathophysiological analysis:
- Alanine Aminotransferase (ALT) vs. Aspartate Aminotransferase (AST): ALT is primarily cytosolic and concentrated within hepatocytes, rendering it highly specific for liver injury. AST is localized within both the cytosol and mitochondria across multiple organ systems (liver, heart, skeletal muscle, brain), making it less organ-specific but diagnostically useful for tracking mitochondrial injury, alcohol-induced damage, or extrahepatic muscle disorders.
- Transamination vs. Oxidative Deamination: Transamination redistributes amino groups between amino acids and keto acids without altering total body nitrogen. In contrast, oxidative deamination (predominantly catalyzed by glutamate dehydrogenase in the mitochondrial matrix) liberates free inorganic ammonium (NH4+) from glutamate, directing toxic nitrogen directly into the urea cycle for systemic excretion.
- Alkaline Phosphatase (ALP) vs. Aminotransferases: While aminotransferases directly reflect hepatocellular parenchymal injury, alkaline phosphatase is a zinc metalloenzyme concentrated within the biliary canalicular membranes. Elevated ALP indicates cholestatic disorders, biliary duct obstruction, or osteoblastic bone turnover rather than direct hepatocyte membrane damage.
- γ-Glutamyl Transferase (GGT) vs. Aminotransferases: GGT is a microsomal enzyme involved in glutathione metabolism. Unlike aminotransferases, GGT rises sharply in response to biliary stasis, alcohol induction, and hepatic microsomal enzyme-inducing medications, often serving to corroborate whether an isolated ALP or transaminase elevation is hepatobiliary in origin.
15. Summary / Key Takeaways
Aminotransferases are vital PLP-dependent enzymes that shuttle amino groups between amino acids and α-keto acids, coordinating cellular nitrogen balance, gluconeogenesis, and the citric acid cycle. While biologically conserved to facilitate rapid, ATP-independent metabolic interconversions, their clinical value is rooted in laboratory diagnostics. Because ALT is predominantly confined to liver parenchyma and AST is distributed throughout metabolic tissues, measuring their absolute concentrations, kinetics, and relative ratios provides clinicians with rapid diagnostic insights into hepatocellular necrosis, toxic insults, skeletal muscle damage, and systemic metabolic disease.
Ultimately, interpreting aminotransferase activity requires balancing molecular kinetics with real-world clinical context. From the historic breakthroughs of Braunstein and Wróblewski to contemporary algorithmic scoring systems, these versatile catalysts continue to bridge foundational biochemistry and everyday clinical practice.
References
- Braunstein, A. E., & Kritzmann, M. G. (1937). Über den Ab- und Aufbau von Aminosäuren durch Umaminierung. Nature, 140(3541), 503–504. https://doi.org/10.1038/140503a0
- De Ritis, F., Coltorti, M., & Giusti, G. (1956). Ferrmentative activities of serum in the diagnosis of viral hepatitis. Minerva Medica, 47(37), 1207–1209.
- Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG Clinical Guideline: Evaluation of abnormal liver biochemistries. The American Journal of Gastroenterology, 112(1), 18–35. https://doi.org/10.1038/ajg.2016.517
- Prati, D., Taioli, E., Zanella, A., Della Torre, E., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., Conte, D., Colombo, M., & Sirchia, G. (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of Internal Medicine, 137(1), 1–10. https://doi.org/10.7326/0003-4819-137-1-200207020-00006
- Schumann, G., Bonora, R., Ceriotti, F., Férard, G., Ferrero, C. A., Franck, P. F., Gella, F. J., Hoelzel, W., Jørgensen, P. J., Kanno, T., Kairisto, V., Lessinger, J. M., & Siekmann, L. (2002). IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clinical Chemistry and Laboratory Medicine, 40(7), 718–724. https://doi.org/10.1515/CCLM.2002.124
- Wróblewski, F., & LaDue, J. S. (1955). Serum glutamic oxalacetic transaminase activity as an index of liver cell injury from experimental tissue damage. Annals of Internal Medicine, 43(2), 345–360. https://doi.org/10.7326/0003-4819-43-2-345